Tavernier G, Galitzky J, Bousquet-Melou A, Montastruc J L, Berlan M
Laboratoire de Pharmacologie Médicale & Clinique, Institut National de la Santé et de la Recherche Médicale, Unité 317, Faculté de Médecine, Toulouse, France.
J Pharmacol Exp Ther. 1992 Dec;263(3):1083-90.
The presence of a beta-3 adrenoceptor (in addition to the classical beta-1 and beta-2 adrenoceptors) and its involvement in the control of heart rate was investigated in the dog. Experiments were carried out in conscious normal and sinoaortic denervated dogs (i.e. animals deprived of baroreceptor pathways). In normal dogs, infusion of isoproterenol, BRL 37344 (4-[-[(2-hydroxy-(3-chlorophenyl) ethyl)-amino]propyl]phenoxyacetate) (a beta-3 adrenergic agonist) or CGP 12177 (4-[3-t-butylamino-2-hydroxypropoxy]benzimidazol-2- one) (a beta-1 beta-2 adrenergic antagonist reported to act as an agonist for the beta-3 adrenergic receptor) increased heart rate with an order of potency: BRL 37344 > isoproterenol >> CGP 12177. [125I]Cyanopindolol binding (2-2000 pM) was saturable and Scatchard analysis indicated the presence of an homogenous population of binding sites. KD was 12.8 +/- 18.5 pM and maximum binding was 94.2 +/- 12.5 fmol/mg of protein. Competition binding studies on dog heart membranes using 150 pM [125I] cyanopindolol indicated an order of potency (CGP 12177 > isoproterenol > BRL 37344) different from that observed in cardiovascular studies. Isoproterenol stimulated adenylate cyclase activity in heart membranes from normal dogs, whereas CGP 12177 and BRL 37344 were without any stimulating action. The positive chronotropic effects of isoproterenol, BRL 37344 and CGP 12177 were accompanied with a reduction in arterial blood pressure. In sinoaortic denervated animals, isoproterenol infusion provoked tachycardia and hypotension. BRL 37344 and CGP 12177 were without any significant effect on heart rate but induced a rapid and dramatic hypotension.(ABSTRACT TRUNCATED AT 250 WORDS)
研究了犬体内β-3肾上腺素能受体(除经典的β-1和β-2肾上腺素能受体外)的存在及其对心率的控制作用。实验在清醒的正常犬和去窦主动脉神经犬(即剥夺压力感受器通路的动物)身上进行。在正常犬中,输注异丙肾上腺素、BRL 37344(4-[-[(2-羟基-(3-氯苯基)乙基)-氨基]丙基]苯氧基乙酸酯)(一种β-3肾上腺素能激动剂)或CGP 12177(4-[3-叔丁基氨基-2-羟基丙氧基]苯并咪唑-2-酮)(一种据报道可作为β-3肾上腺素能受体激动剂的β-1β-2肾上腺素能拮抗剂)可使心率增加,其效力顺序为:BRL 37344>异丙肾上腺素>>CGP 12177。[125I]氰吲哚洛尔结合(2 - 2000 pM)具有饱和性,Scatchard分析表明存在同质的结合位点群体。解离常数(KD)为12.8±18.5 pM,最大结合量为94.2±12.5 fmol/mg蛋白质。使用150 pM[125I]氰吲哚洛尔对犬心脏膜进行的竞争结合研究表明,其效力顺序(CGP 12177>异丙肾上腺素>BRL 37344)与心血管研究中观察到的不同。异丙肾上腺素刺激正常犬心脏膜中的腺苷酸环化酶活性,而CGP 12177和BRL 37344没有任何刺激作用。异丙肾上腺素、BRL 37344和CGP 12177的正性变时作用伴随着动脉血压的降低。在去窦主动脉神经的动物中,输注异丙肾上腺素会引发心动过速和低血压。BRL 37344和CGP 12177对心率没有任何显著影响,但会导致快速而显著的低血压。(摘要截短至250字)